June 08,2010

Lumixyl™'s innovative peptide technology was the subject of a feature article by Dr. Neil Sadick (New York, NY) in the April 2010 issue of Cosmetic Dermatology, entitled "Novel Synthetic Oligopeptide Formulation Offers Nonirritating Cosmetic Alternative for Treatment of Melasma."

The article discusses the Lumixyl™ peptide's proven ability to inhibit tyrosinase more effectively than hydroquinone and without the associated cytotoxicity. Specifically, the article puts Lumixyl™ 's revolutionary ability in context, stating: "Currently used skin-lightening agents for melasma are either both effective and cytotoxic, or slightly effective and non-toxic." Lumixyl™  has been demonstrated to be effective and non-cytotoxic in the inhibition of tyrosinase.

Indeed, the article's overview of commonly used brightening agents does well in setting Lumixyl™ above the rest. In addition to citing the emerging safety concerns regarding Hydroquinone (HQ), the authors similarly consider Kojic acid, Azelaic acid and Ascorbic acid (Vitamin C) and review some of the issues of irritation, oxidation and cytotoxicity that affect these.

Though the article was written prior to the launch of the Lumixyl Brightening System, the authors do take care to discuss the utility of combining the Lumixyl™ cream with an exfoliant for faster results.

The full article can be accessed here.

For more information on Lumixyl™, please contact info@basismedtech.com or call 1-877-944-1974